Dianthus Therapeutics (DNTH) Equity Average (2018 - 2025)
Historic Equity Average for Dianthus Therapeutics (DNTH) over the last 7 years, with Q3 2025 value amounting to $424.8 million.
- Dianthus Therapeutics' Equity Average rose 2203.9% to $424.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $424.8 million, marking a year-over-year increase of 2203.9%. This contributed to the annual value of $260.7 million for FY2024, which is 31874.59% up from last year.
- Per Dianthus Therapeutics' latest filing, its Equity Average stood at $424.8 million for Q3 2025, which was up 2203.9% from $315.8 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Equity Average ranged from a high of $424.8 million in Q3 2025 and a low of -$56.1 million during Q2 2023
- In the last 4 years, Dianthus Therapeutics' Equity Average had a median value of $173.6 million in 2023 and averaged $189.9 million.
- Its Equity Average has fluctuated over the past 5 years, first crashed by 13914.02% in 2023, then soared by 75096.63% in 2024.
- Dianthus Therapeutics' Equity Average (Quarter) stood at -$39.6 million in 2022, then surged by 538.88% to $173.6 million in 2023, then skyrocketed by 98.81% to $345.2 million in 2024, then grew by 23.05% to $424.8 million in 2025.
- Its Equity Average stands at $424.8 million for Q3 2025, versus $315.8 million for Q2 2025 and $340.5 million for Q1 2025.